High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer-Reference-Cited by-同舟云学术

High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer

Published:2014-12 Issue:12a Volume:44 Page:1188-1192
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Stone E.¹²,Allen H. A.¹²,Saghaie T.³,Abbott A.³,Daniel R.³,Mead R. S.⁴⁵,Kohonen-Corish M.⁵,Plit M.¹,Morgan L.³

Affiliation:

1. St Vincent's Hospital Sydney; Sydney New South Wales Australia

2. Kinghorn Cancer Centre; Sydney New South Wales Australia

3. Nepean Lung Cancer Group; Nepean Blue Mountains LHD; Sydney New South Wales Australia

4. SydPath; Sydney New South Wales Australia

5. Garvan Institute of Medical Research; Sydney New South Wales Australia

Funder

Roche Products

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.12587/fullpdf

Reference19 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial;Mitsudomi;Lancet Oncol,2010

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer;Translational Oncology;2024-11

2. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology;Therapeutic Advances in Medical Oncology;2024-01

3. Chitinase 3-like-1 (CHI3L1) in the Pathogenesis of Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer;2023-09-23

4. The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations;Contrast Media & Molecular Imaging;2022-10-11

5. EGFR mutation profile in Australian patients with non-small cell lung cancer;Pathology;2021-12